242 related articles for article (PubMed ID: 17164050)
1. Therapeutic advances for glioblastoma multiforme: current status and future prospects.
Robins HI; Chang S; Butowski N; Mehta M
Curr Oncol Rep; 2007 Jan; 9(1):66-70. PubMed ID: 17164050
[TBL] [Abstract][Full Text] [Related]
2. Towards tailored therapy of glioblastoma multiforme.
Rekers NH; Sminia P; Peters GJ
J Chemother; 2011 Aug; 23(4):187-99. PubMed ID: 21803695
[TBL] [Abstract][Full Text] [Related]
3. The potential use of tideglusib as an adjuvant radio-therapeutic treatment for glioblastoma multiforme cancer stem-like cells.
Bou-Gharios J; Assi S; Bahmad HF; Kharroubi H; Araji T; Chalhoub RM; Ballout F; Harati H; Fares Y; Abou-Kheir W
Pharmacol Rep; 2021 Feb; 73(1):227-239. PubMed ID: 33140310
[TBL] [Abstract][Full Text] [Related]
4. Stereotactic radiosurgery and bevacizumab for recurrent glioblastoma multiforme.
Cabrera AR; Cuneo KC; Vredenburgh JJ; Sampson JH; Kirkpatrick JP
J Natl Compr Canc Netw; 2012 Jun; 10(6):695-9. PubMed ID: 22679114
[TBL] [Abstract][Full Text] [Related]
5. Temozolomide and thalidomide in the treatment of glioblastoma multiforme.
Riva M; Imbesi F; Beghi E; Galli C; Citterio A; Trapani P; Sterzi R; Collice M
Anticancer Res; 2007; 27(2):1067-71. PubMed ID: 17465245
[TBL] [Abstract][Full Text] [Related]
6. Phase II clinical study of boron neutron capture therapy combined with X-ray radiotherapy/temozolomide in patients with newly diagnosed glioblastoma multiforme--study design and current status report.
Kawabata S; Miyatake S; Hiramatsu R; Hirota Y; Miyata S; Takekita Y; Kuroiwa T; Kirihata M; Sakurai Y; Maruhashi A; Ono K
Appl Radiat Isot; 2011 Dec; 69(12):1796-9. PubMed ID: 21459588
[TBL] [Abstract][Full Text] [Related]
7. [Treatment possibilities in patients with glioblastoma multiforme].
Naydenov E; Tzekov C; Bussarsky V; Nachev S; Tzekova V; Hadjieva T
Khirurgiia (Sofiia); 2010; (4-5):36-41. PubMed ID: 21972682
[TBL] [Abstract][Full Text] [Related]
8. Combined modality treatment of glioblastoma multiforme: the role of temozolomide.
Nieder C; Adam M; Grosu AL
Rev Recent Clin Trials; 2006 Jan; 1(1):43-51. PubMed ID: 18393779
[TBL] [Abstract][Full Text] [Related]
9. The PI3K inhibitor GDC-0941 enhances radiosensitization and reduces chemoresistance to temozolomide in GBM cell lines.
Shi F; Guo H; Zhang R; Liu H; Wu L; Wu Q; Liu J; Liu T; Zhang Q
Neuroscience; 2017 Mar; 346():298-308. PubMed ID: 28147244
[TBL] [Abstract][Full Text] [Related]
10. Management of glioblastoma.
Aoki T; Hashimoto N; Matsutani M
Expert Opin Pharmacother; 2007 Dec; 8(18):3133-46. PubMed ID: 18035958
[TBL] [Abstract][Full Text] [Related]
11. Evolution of care for patients with relapsed glioblastoma.
Balañá C; Villá S; Teixidor P
Expert Rev Anticancer Ther; 2011 Nov; 11(11):1719-29. PubMed ID: 22050021
[TBL] [Abstract][Full Text] [Related]
12. Molecular pathways and potential therapeutic targets in glioblastoma multiforme.
Wardak Z; Choe KS
Expert Rev Anticancer Ther; 2013 Nov; 13(11):1307-18. PubMed ID: 24168050
[TBL] [Abstract][Full Text] [Related]
13. Temozolomide in radio-chemotherapy combined treatment for newly-diagnosed glioblastoma multiforme: phase II clinical trial.
Lanzetta G; Campanella C; Rozzi A; Nappa M; Costa A; Fedele F; Innocenzi G; Gagliardi FM; Salvati M; Minniti G; Frati A; Frati L; Vecchione A
Anticancer Res; 2003; 23(6D):5159-64. PubMed ID: 14981983
[TBL] [Abstract][Full Text] [Related]
14. Prognostic factors other than the performance status and age for glioblastoma multiforme: a single-institution experience.
Caloglu M; Yurut-Caloglu V; Karagol H; Bayir-Angin G; Turan FN; Uzal C
J BUON; 2009; 14(2):211-8. PubMed ID: 19650168
[TBL] [Abstract][Full Text] [Related]
15. Distance to the neurooncological center: a negative prognostic factor in patients with glioblastoma multiforme. An epidemiological study.
Kerschbaumer J; Freyschlag CF; Bauer R; Obwegeser AA; Schubert GA; Thomé C; Seiz M
Anticancer Res; 2012 Dec; 32(12):5515-9. PubMed ID: 23225460
[TBL] [Abstract][Full Text] [Related]
16. Current therapies for glioblastoma.
Yung WK
Clin Adv Hematol Oncol; 2004 Sep; 2(9):572-3. PubMed ID: 16163238
[No Abstract] [Full Text] [Related]
17. Phase III trial of accelerated hyperfractionation with or without difluromethylornithine (DFMO) versus standard fractionated radiotherapy with or without DFMO for newly diagnosed patients with glioblastoma multiforme.
Prados MD; Wara WM; Sneed PK; McDermott M; Chang SM; Rabbitt J; Page M; Malec M; Davis RL; Gutin PH; Lamborn K; Wilson CB; Phillips TL; Larson DA
Int J Radiat Oncol Biol Phys; 2001 Jan; 49(1):71-7. PubMed ID: 11163499
[TBL] [Abstract][Full Text] [Related]
18. Clinical trial of external beam-radiotherapy combined with daily administration of low-dose cisplatin for supratentorial glioblastoma multiforme--a pilot study.
Shinoda J; Sakai N; Hara A; Ueda T; Sakai H; Nakatani K
J Neurooncol; 1997 Oct; 35(1):73-80. PubMed ID: 9266443
[TBL] [Abstract][Full Text] [Related]
19. Current status and future therapeutic perspectives of glioblastoma multiforme (GBM) therapy: A review.
Anjum K; Shagufta BI; Abbas SQ; Patel S; Khan I; Shah SAA; Akhter N; Hassan SSU
Biomed Pharmacother; 2017 Aug; 92():681-689. PubMed ID: 28582760
[TBL] [Abstract][Full Text] [Related]
20. Increased cure rate of glioblastoma using concurrent therapy with radiotherapy and arsenic trioxide.
Ning S; Knox SJ
Int J Radiat Oncol Biol Phys; 2004 Sep; 60(1):197-203. PubMed ID: 15337556
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
